Cardiovascular Disease
Conditions
Brief summary
This study has been designed as a randomized, double-blind trial to provide definitive evidence on the effects of ticagrelor and prasugrel on myocardial salvage in patients with anterior ST Segment Elevation Myocardial Infarction (STEMI) undergoing primary Percutaneous Coronary Intervention (PCI). This study will also measure the effects of ticagrelor vs. prasugrel on secondary endpoints listed above. This study design aims to test the hypothesis that ticagrelor will reduce myocardial infarct size as a proportion of the ischemic area at risk when compared to prasugrel.
Detailed description
Subjects and research staff (including the Magnetic Resonance Imaging (MRI) readers and interventional cardiologists) will not know what active treatment study drug the subjects are receiving. Study Arm 1: Ticagrelor (180 mg loading dose, followed by 90 mg twice a day) PO plus matching placebo Study Arm 2: Prasugrel (60 mg loading dose followed by 5 or 10 mg once per day based on weight) PO plus matching placebo Additional study drug: Aspirin (81mg per day) Participation in this study will be about 90 days and includes 4 study visits (other than your hospital stay) and 3 telephone calls. ENROLLMENT PROCEDURES: The following procedures are to be completed after informed consent has been obtained: * Informed Consent Form signed * Medical history * Vital signs (eg, blood pressure, heart rate, respiration rate, temperature) * Review for Adverse Events (AEs) and Serious Adverse Events (SAEs) (only AEs possibly related to study procedures and SAEs are collected) * Documentation of concomitant medications * Physical exam * Body height * Body weight * 12-lead Electrocardiogram (ECG) * Angiographic and Percutaneous Coronary Intervention (PCI) data * Randomization of treatment assignment * Investigational product dispensing (on Day 0 and during hospital stay) - Loading dose on Day 0 - 3 day investigational product dosing while in the hospital - 30 day supply dispensing of investigational product on Day 3 for subject to take home * Local laboratory Assessments: - Blood draw for Creatine Kinase-MB (CK-MB) and troponin I - Blood pregnancy (females of childbearing potential only) FOLLOW UP PROCEDURES: Day 5 * Vital signs (e.g., blood pressure, heart rate, respiration rate, temperature) * Review for Adverse Events and Serious Adverse Events (only AEs possibly related to study procedures and SAEs are collected) * Cardiac MRI * Left Ventricular Ejection Fraction (LVEF), Left Ventricular End-Diastolic Volume (LVEDV), Left Ventricular End-Systolic Volume (LVESV) calculations * Serum creatinine, Complete Blood Count (CBC) * Documentation of concomitant medications and investigational product compliance Day 30 (+/- 1 day), Day 60 (+/- 2 days) * Vital signs (e.g., blood pressure, heart rate, respiration rate, temperature) * Review for Adverse Events and Serious Adverse Events (only AEs possibly related to study procedures and SAEs are collected) * LVEF, LVEDV, LVESV calculations * Serum creatinine, CBC * Documentation of concomitant medications and investigational product compliance * Investigational Product Dispensing Day 14, Day 44, Day 74 (+/- 2 days): Phone calls will be performed to ensure drug compliance, review concomitant medications and review any events. On Day 74, study staff will confirm whether or not the subject has seen their regular cardiologist. Subject will be instructed to bring this information with them at the Day 90 visit so that their cardiologist can be told what arm they participated in for continuation of care and medication therapy. Day 90 or Termination/End of Study (+/- 2 days) : * Vital signs (eg, sitting blood pressure, heart rate, respiration rate, temperature) * Review for Adverse Events and Serious Adverse Events (only AEs possibly related to study procedures and SAEs are collected) * Cardiac MRI * LVEF, LVEDV, LVESV calculations * Serum creatinine, CBC * Documentation of concomitant medications and investigational product compliance * If available and subject consents, subject's cardiologist will be informed what arm of the study they participated in for continuation of care and medication therapy.
Interventions
DRUGticagrelor
A platelet aggregation inhibitor
DRUGprasugrel
a thienopyridine class inhibitor of platelet activation and aggregation
DRUGPlacebo
placebo
Sponsors
AstraZeneca
Yochai Birnbaum
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Informed consent: Signed informed consent prior to any study specific procedures 2. Age: Male and females aged 18 years and older 3. Onset: Presenting to emergency room or cardiac catheterization laboratory within 6 hours of onset of myocardial infarction symptoms 4. Continuing to have ongoing myocardial infarction symptoms 5. EKG findings: ST elevation on ECG with positive T waves in the precordial leads, suggestive of anterior STEMI 6. Triaged for emergency cardiac catheterization (primary PCI protocol) 7. Agree to use an effective contraceptive method beginning at the signing of the informed consent and for at least 30 days after the last dose of study drug. The definition of an effective method of contraception will be based on the judgment of the investigator.
Exclusion criteria
1. Prior myocardial infarction 2. Contraindication to ticagrelor and/or prasugrel 3. Contraindication to gadolinium 4. Contraindication to aspirin 5. Treatment with fibrinolytic therapy for the index STEMI 6. High risk of bleeding 7. Presenting with cardiogenic shock 8. Infarction due to stent thrombosis 9. History of a previous coronary artery bypass graft (CABG) 10. Known renal insufficiency (acute kidney injury or Glomerular Filtration Rate \< 40 mL/min/1.73 m2). 11. Moderate or severe hepatic impairment 12. Inability to undergo cardiac MRI 13. Indication for aspirin \>162 mg/d 14. Indication for Nonsteroidal Anti-Inflammatory Drugs or COX2 inhibitors 15. Pregnant 16. Breast feeding 17. History of intracranial hemorrhage
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy as measured by infarct size on all randomized patients. | up to Day 90 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety as measured by incidences of treatment emergent adverse events, serious adverse events, treatment-related adverse events and adverse events leading to stop of drug | 90 days | for 90 day major adverse cardiac events and bleeding complications |
Countries
United States
Outcome results
None listed